| Ytd | -9.99% | |
| 1y | -0.60% |
| Open | 24.92 | Prev Close | 24.67 | Low | 24.26 | High | 25.18 | Mkt Cap | 2.58B |
| Vol | 2.29M | Avg Vol | 2.14M | EPS | -0.69 | P/E | N/A | Forward P/E | -5.26 |
| Beta | 2.23 | Short Ratio | 15.84 | Inst. Own | 107.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-03 | 50-d Avg | 27.39 | 200-d Avg | 28.59 | 1yr Est | 52.15 |
BEAM News
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
LOS ANGELES--(BUSINESS WIRE)---- $BEAM--BEAM Investors Have Opportunity to Join Beam Therapeutics In
[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation fi
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
Short sellers are making bold bets, and the numbers behind those bets are getting harder to ignore.
These 10 heavily shorted stocks face potential reversals, led by Venture Global, followed by CleanSp
Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform a
Beam Therapeutics reported positive Phase 1/2 trial data for BEAM-302 to treat AATD, targeting accel
With Up to 18 Months Follow-Up, Data Show Long-Term Durability of In Vivo Correction of Disease-caus
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) wi